Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Holding QURE?
Track your performance easily
QURE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.73 - $11.35
Previous Close$5.62
Volume672.01K
Average Volume (3M)2.87M
Market Cap
$273.68M
Enterprise Value$104.30M
Total Cash (Recent Filing)$287.88M
Total Debt (Recent Filing)$118.50M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Oct 29, 2024EPS Estimate
-$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.92
Shares Outstanding48,697,619
10 Day Avg. Volume414,706
30 Day Avg. Volume2,865,958
Standard Deviation0.19
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.89
Price to Sales (P/S)9.88
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.76
Enterprise Value/Gross Profit47.09
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$18.60Price Target Upside222.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
uniQure News
PremiumCompany Announcements
uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment
Bulls Say, Bears Say
Bulls Say
Financial PositionEnded 2Q24 with approximately $524M in cash, which uniQure expects, together with the estimated savings from the restructuring measures, should fund operations through the end of.
Gene Therapy ProgramsMultiple gene therapy pipeline programs advancing in Phase 1/2.
Regulatory ProgressQURE was granted the RMAT designation in June that allows sponsors to have early and frequent interactions with the FDA, enabling increased collaboration and the opportunity for expedited product development.
Bears Say
Financial PerformanceIf the agency requires a long-term, large Phase 3 study that would cost hundreds of millions of dollars and 5-6 years, that would be beyond QURE's means, and they would pursue a potential partnership.
Product PipelineThere is no other near-term commercial gene-therapy product to help generate cash needed to support the high operational costs of owning a gene-therapy manufacturing facility.
Regulatory UncertaintyThe lack of clarity on the regulatory path for AMT-130 leads to maintaining a Neutral rating.
---
Ownership Overview
4.38% Insiders
11.99% Mutual Funds
36.41% Other Institutional Investors
47.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $3.73 and its highest was $11.35 in the past 12 months.
What is uniQure N.V.’s market cap?
Currently, no data Available
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Oct 29, 2024 which is in 39 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Aug 01, 2024. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.253 by $0.093.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -$1.01.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 48,697,620 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.253. Following the earnings report the stock price went down -2.35%.
Which hedge fund is a major shareholder of uniQure N.V.?
Among the largest hedge funds holding uniQure N.V.’s share is Bridger Management, LLC. It holds uniQure N.V.’s shares valued at 2M.
---
uniQure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.60 (222.92% Upside)
$18.60 (222.92% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.04%
12-Months-Change
Fundamentals
Return on Equity
-126.41%
Trailing 12-Months
Asset Growth
-22.48%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
---
QURE Stock 12 Month Forecast
Average Price Target
$18.60
▲(222.92% Upside)
Technical Analysis
Best Analysts Covering QURE
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+7.04%
reiterated a buy rating 2 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +7.04% per trade.
---